Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | F2RL3 | Q96RI0 | 8/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | GPR6 | P46095 | 1/20 | 0.36 |
| ▸ | REV1 | Q9UBZ9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3010626 | 0.93 | ALDH1A1 (0.45) | ALDH1A1HPGDHSD17B10L3MBTL1MAPT | |
| SCHEMBL3006114 | 0.93 | MAPT (0.40) | ALDH1A1HPGDHSD17B10L3MBTL1MAPT | |
| SCHEMBL3009170 | 0.93 | MAPT (0.39) | ALDH1A1HPGDHSD17B10L3MBTL1MAPT | |
| SCHEMBL3007265 | 0.92 | MAPT (0.39) | ALDH1A1HPGDHSD17B10L3MBTL1MAPT | |
| SCHEMBL3018545 | 0.92 | ALDH1A1 (0.41) | ALDH1A1HPGDHSD17B10L3MBTL1MAPT | |
| SCHEMBL3014972 | 0.91 | MAPT (0.38) | ALDH1A1HPGDHSD17B10L3MBTL1MAPT | |
| SCHEMBL3011687 | 0.91 | MAPT (0.38) | ALDH1A1HPGDHSD17B10L3MBTL1MAPT | |
| SCHEMBL3012493 | 0.90 | L3MBTL1 (0.40) | ALDH1A1HPGDHSD17B10L3MBTL1MAPT | |
| SCHEMBL3016598 | 0.90 | MAPT (0.43) | ALDH1A1HPGDHSD17B10L3MBTL1MAPT | |
| SCHEMBL3015933 | 0.90 | MAPT (0.41) | ALDH1A1HPGDHSD17B10MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | ALDH1A1 3510/4885HPGD 2894/4885HSD17B10 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.